CALCITRIOL-ODAN CAPSULE

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Osta se nyt

Lataa Valmisteyhteenveto (SPC)
03-10-2014

Aktiivinen ainesosa:

CALCITRIOL

Saatavilla:

ODAN LABORATORIES LTD

ATC-koodi:

A11CC04

INN (Kansainvälinen yleisnimi):

CALCITRIOL

Annos:

0.25MCG

Lääkemuoto:

CAPSULE

Koostumus:

CALCITRIOL 0.25MCG

Antoreitti:

ORAL

Kpl paketissa:

30/100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

VITAMIN D

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0113628007; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2014-09-24

Valmisteyhteenveto

                                PRODUCT MONOGRAPH
PR CALCITRIOL-ODAN
TM
Calcitriol
Capsules 0.25 mcg and 0.5 mcg
House standard VITAMIN D
3 METABOLITE
ODAN LABORATORIES LTD.
DATE OF PREPARATION:
325 STILLVIEW AVENUE
SEPTEMBER 23, 2014
POINTE-CLAIRE, QC
CANADA H9R 2Y6
Submission Control No: 161455
CALCITRIOL-ODAN
TM
is a trade-mark of Odan Laboratories Limited.
_Page 1 of 25_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL USE
.............................................................................3
CONTRAINDICATIONS
..................................................................................................3
WARNINGS AND PRECAUTIONS
.................................................................................4
ADVERSE REACTIONS
...................................................................................................5
DRUG INTERACTIONS
...................................................................................................7
DOSAGE AND ADMINISTRATION
...............................................................................8
OVERDOSAGE
...............................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
...........................................................11
STORAGE AND STABILITY
.........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................12
PART II: SCIENTIFIC INFORMATION
..............................................................................14
PHARMACEUTICAL INFORMATION
.........................................................................14
CLINICAL TRIALS
.........................................................................................................14
DETAILED PHARMACOLOGY
.......................
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Valmisteyhteenveto Valmisteyhteenveto ranska 23-09-2014

Etsi tähän tuotteeseen liittyviä ilmoituksia